IOmx Therapeutics AG | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
IOmx Therapeutics AG

BRIEF

published on 08/22/2024 at 10:05, 2 months 29 days ago

IOmx Therapeutics Initiates Phase Ib with OMX-0407

Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF

published on 08/22/2024 at 10:05, 2 months 29 days ago

IOmx Therapeutics lance la phase Ib avec OMX-0407

Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE

published on 08/22/2024 at 10:00, 2 months 29 days ago

iOmx Therapeutics Initiates Phase Ib with OMX-0407
iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma

Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF

published on 06/27/2024 at 10:05, 4 months 23 days ago

IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
BRIEF

published on 06/27/2024 at 10:05, 4 months 23 days ago

IOmx Therapeutics nomme Florian Schmid au poste de directeur financier

Biopharmaceutique Direction Directeur Financier Florian Schmid IOmx Thérapeutique
PRESS RELEASE

published on 06/27/2024 at 10:00, 4 months 23 days ago

iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer
iOmx Therapeutics appoints Florian Schmid as new Chief Financial Officer, succeeding Marcus Irsfeld. Schmid brings 20+ years of financial leadership experience in biopharma. Company aims to advance immuno-oncology drug candidates

Chief Financial Officer Biopharmaceutical Immuno-oncology IOmx Therapeutics Florian Schmid
PRESS RELEASE

published on 11/01/2023 at 10:00, 1 year ago

iOmx Therapeutics attends upcoming scientific and industry conferences
PRESS RELEASE

published on 09/05/2023 at 08:30, 1 year 2 months ago

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
PRESS RELEASE

published on 04/04/2023 at 10:00, 1 year 7 months ago

iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial
PRESS RELEASE

published on 02/23/2023 at 10:00, 1 year 8 months ago

iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer

Accesswire

Published on 11/21/2024 at 09:00, 47 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 12 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 22 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 47 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 47 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 46 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 47 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 47 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 32 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 37 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 39 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 27 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE